Rainbow Biosciences, a wholly owned subsidiary of Rainbow Coral Corp., is working to market and develop an innovative new 3D bioprinting system, leveraging momentum in the broader bioprinting industry. New 3D printing innovations reveal increasing numbers of applications to the medical field, generating massive demand for the 3D printing technology from patients and doctors.
A British surgeon recently used the latest 3D printing techniques to create a new pelvis for a man who had lost half of his own to bone cancer. The groundbreaking transplant was the first of its kind, but only one of numerous medical breakthroughs and applications to arise through 3D printing. 3D printers have been used to create prosthetic limbs, custom hearing aids and even human tissues.
Rainbow Biosciences reports that through its joint venture with Nano3D Biosciences (n3D), the company is well-positioned to capitalize on the rise of 3D printing in the medical field. The joint venture intends to market and develop the BiO Assay, the first commercially available 3D bioprinter designed specifically for rapid, high-volume drug screening.
The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures at a more affordable cost than competing bioprinting technology currently on the market. Rainbow Biosciences believes that the BiO Assay represents a significant change in pharmaceutical research, offering unprecedented superior and faster results.
For more information visit www.RainbowBioSciences.com
Let us hear your thoughts below:
